UPDATE: Deutsche Bank Upgrades Omeros
Deutsche Bank raises its rating on Omeros (NASDAQ: OMER) to Buy from Hold and raies its price target $5 to $11 following strong top-line data for the company's intraocular lens replacement surgery.
Deutsche Bank says, "Following the release of strong, topline Ph 3 OMS302 data for intraocular lens replacement surgery, we upgraded Omeros shares from HOLD to BUY early Tuesday morning as we see a reduction in the overall risk profile for the co's PharmacoSurgery platform (OMS103HP, OMS302, OMS201) – key valuation driver. Moreover, we have not ascribed any value to OMER's early stage biotech pipeline, the GPCR program, as well as its preclinical CNS product candidates – which could potentially yield lucrative collaborations."
OMER closed at $10.22 a share on Tuesday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.